News
Sanofi-aventis and Kyowa Hakko Kirin enter into a Collaboration and Licensing Agreement on an Anti LIGHT fully human monoclonal antibody – 5/14/09
Click here to view press release
Announcement of Phase 1 Study for KRN23 - 2/13/2009
Kyowa Hakko Kirin announces the initiation of Phase 1-clinical trial of KRN23, a novel IV drug discovered by KHK for the treatment of X-linked Hypophosphatemia (XLH). XLH is a genetic metabolic condition which affects bone and teeth development.
Kirin Pharma USA, Inc. Name Change Announcement - 1/1/2009
As of January 1, 2009, Kirin Pharma USA has changed its name to Kyowa Hakko Kirin California, Inc.
Merger between Kirin Pharma Co., Ltd. and Kyowa Hakko Kogyo Co., Ltd. 10/1/2008
On October 1, 2008, Kirin Pharma Company, Limited merged with Kyowa Hakko Kogyo Company, Limited. under the initiative of Kirin Holdings Company, Limited, to become Kyowa Hakko Kirin Company, Limited.
Strategic Alliance Between Kyowa Hakko Group and Kirin Group: 10/22/2007
Kyowa Hakko Kogyo Co., Ltd. (President and CEO, Yuzuru Matsuda, "Kyowa Hakko"), Kirin Pharma Company, Limited (President and Chairman of the Board of Directors, Katsuhiko Asano, "Kirin Pharma") and Kirin Holdings Company, Limited (President and CEO, Kazuyasu Kato, "Kirin Holdings") have reached an agreement with respect to a strategic alliance between the Kyowa Hakko Group and the Kirin Group targeting the overall businesses of both groups (the "Strategic Alliance") and accordingly, on October 22, 2007, entered into an integration agreement. Both groups will promote the business collaboration arising from the Strategic Alliance, enhance competitiveness and management efficiency, maximize synergy and will aim to improve their corporate values through further development.
Gemini Science, Inc. Name Change Announcement 07/1/2007
Please be advised that as of July 1, 2007, Gemini Science, Inc. has a new name - Kirin Pharma USA, Inc.
Science Research Park
Building Dedication Event 7/12/2006
On July 12, 2006 Kirin Pharma USA, Inc., together with the La Jolla Institute for Allergy and Immunology celebrated the opening our new state of the art facility located on the UCSD campus.
Corporate Program Series:
US-Japan BioBridge: 2/22/2006
Kazuo Kawamura, President of Kirin Pharma USA, was invited to be a panelist at the US-Japan BioBridge symposium organized by the Japan Society of San Diego and Tijuana. He spoke about his ideas on business between Japan and the US. Dr. Kawamura is a member of the Board of Directors of the Japan America Society of San Diego and Tijuana.
M2 Project Press Release: 12/17/2005
Kirin Pharma USA Announces Development of a Novel Anti-Influenza Therapeutic Preliminary Data Presented at the 45th ICAAC Meeting Demonstrates Potential Against Multiple Influenza Strains, Including Avian Influenza Strain, H5N1.
Science Research Park:
Future Home of Kirin Pharma USA, Inc.
The University of California, San Diego (UCSD) has developed a new project named the Science Research Park. This project was designed to facilitate collaboration between academia and industries in order to develop innovative therapies and medicine. LIAI and Kirin Pharma USA are now participating in his project, and have started construction of our new research building on the UCSD Science Research Park campus. We plan to move into this new 130,000+ sq.ft. facility in 2006. UCSD has also announced the opening of the Rebecca and John Moores UCSD Cancer Center in April 2005, also located on the Science Research Park campus. Kirin Pharma USA looks forward to collaborating with them as well.
To read more about the UCSD Science Research Park and Kirin Pharma USA, please see the following press release articles listed below.
UCSD Marks Major Milestone with Premier Groundbreaking in Science Research Park: 2/17/05
Work on Research Center Starting: 2/17/05
Groundbreaking for new Science Research Park to be held on Thursday: 2/13/05
